Navigation Links
Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
Date:12/12/2011

LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that its investigational product candidate MYDICAR® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced heart failure.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

"The positive results of the phase 2 CUPID Trial demonstrated the potential of MYDICAR® to become an important treatment for patients with chronic, advanced heart failure," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp.  Dr. Zsebo continued, "Today we are pleased that the FDA recognizes the potential benefit of MYDICAR® to address the enormous unmet medical need for additional therapeutics to treat advanced heart failure patients by granting the program Fast Track Status."

About the CUPID Trial

The previously announced results of the phase 2 CUPID Trial met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR® versus placebo. Additionally, 12 months after receiving a single infusion of MYDICAR®, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003) of major cardiovascular events such as death, need for left ventricular assist device (LVAD) or cardiac transplant, episodes of worsening heart failure and number of heart failure-related hospitalizations.

The mean duration of hospitalization in the MYDICAR® high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially n
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
2. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
3. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
4. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
5. Leatt Corporation Announces 2011 Annual Shareholders Meeting
6. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
7. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
8. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
9. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012
10. Ansell Limited Acquires a Minority Share in Yulex Corporation
11. The Female Health Companys Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... Dec. 22, 2014   TRU-D SmartUVC LLC, ... disinfection robot, announced today that the General Services Administration ... November 2019.   This newly formed agreement ... levels of government purchasers, including Department of Veteran Affairs ... Homeland Security contacts purchasing solutions for the Ebola effort ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
(Date:12/24/2014)... For chic ladies, new fashionable outfits are ... of their Holiday Wish List, Angeldress.co.uk has chosen ... to accent ladies’ holiday wardrobe by launching a promotion on ... over the discount of 80% off, like a cheap suit. ... The company’s chic wedding dresses are among the hottest items ...
(Date:12/24/2014)... The 2014 Market Research Report ... in-depth research report on COC industry. For an ... including its definition, classification, application, industry chain structure, ... report also presents product specification, manufacturing process, and ... regions, technology and applications. Analysis also covers upstream ...
(Date:12/24/2014)... December 24, 2014 Verde Pointe Dental Associates ... ever. "Last years homemade Christmas sweater lit up, but ... The 2014 winner is Tandy Wilson for the second year ... enthusiast," says Kirk Kimmerling DDS. "She took pictures of the ... the sweater." , "Every year I enjoy stopping ...
(Date:12/24/2014)... 24, 2014 “ Relax Melodies ” ... AppWatch, which features the latest and coolest mobile applications ... a mobile technology expert and host of NewsWatch, conducted ... application soothes users so they can fall asleep. , ... adults say they have some sort of difficulty sleeping. ...
(Date:12/24/2014)... Aliso Viejo, California (PRWEB) December 24, 2014 ... the release of the ProDenoise from Pixel Film Studios. , ... film noise or grain in their footage,” said Christina Austin, ... to have in any Final Cut Pro X editors toolbox.” ... subdue film noise or grain in their footage with ProDenoise ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2
... Pa., Oct. 15 ViroPharma Incorporated,s (Nasdaq: VPHM ) ... released on Wednesday, October 28, 2009 before the open of ... conference call and live audio webcast at 9:00 a.m. Eastern ... ViroPharma management will discuss the 2009 third quarter and other ...
... ROCHESTER, Minn., Oct. 15 Mayo Clinic clinicians and ... and tested a tool to involve patients more in ... set of decision aid cards, could help patients make ... outcomes. The results of this randomized trial are in ...
... UV radiation, researchers say , THURSDAY, Oct. 15 ... are better than yellow at protecting skin against damaging ... scientists. , The researchers said their findings could lead ... The color of fabric is one of the most ...
... Passes Veterans Health Care Budget Reform and Transparency Act of ... Federation of Government Employees, today, lauded the efforts of Congress ... health care provided by the Department of Veterans Affairs. For ... in the VA funding process. AFGE applauds these members of ...
... , FAIRFAX, Va., Oct. 15 Four ... new, non-profit association, the Association of Gamete Donor Providers ... to share information and services, enhance educational programs and ... involved in all aspects of building families with the ...
... companies have been doing it for years. Why not ... thoughtful discussion in hospitals and as a way to ... secondary markets. One developer, North Carolina-based Oaks ... medical office buildings (MOBs). As such, the innovative developer ...
Cached Medicine News:Health News:ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009 2Health News:Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 2Health News:Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 3Health News:Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 4Health News:VA Funding Reform Bill Clears Congress 2Health News:Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 2
... Modes of Operation: , Standby: All toggle switches ... 60-ms bursts of 50 Hz separated by .75 s; ... pulse/s); single or repeat , Tetanus: 50 Hz ... Single (4 pulses/2 s); repeat (4 pulses/2 s; repeats ...
... of Operation: , Standby: All toggle switches at ... (1 pulse/s); 10 s (1 pulses/10 s) , ... (100 pulses/s) , Train-Of-Four: Single (4 pulses/2 s); ... , Output Current: Adjustable from 0-70 mA(HI range) ...
... of Operation: , Double Burst : 2 60-ms bursts ... 1 s (1 pulse/s) , Tetanus: 50 Hz ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: Adjustable ... Monophasic pulses (200-us duration) , Indicators: Battery LED (green) ...
... standby switch maintains power to the instrument without ... pulse/s) , Tetanus: 100 Hz (200 pulses/s) ... Current: Adjustable from 0-70 mA , Stimulus ... Indicators: Battery LED (green) indicates that the units ...
Medicine Products: